Oak Ridge Investments LLC Sells 402 Shares of Glaukos Corporation $GKOS

Oak Ridge Investments LLC lessened its position in shares of Glaukos Corporation (NYSE:GKOS) by 3.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,695 shares of the medical instruments supplier’s stock after selling 402 shares during the period. Oak Ridge Investments LLC’s holdings in Glaukos were worth $1,105,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP raised its stake in Glaukos by 6.1% during the first quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier’s stock worth $225,460,000 after buying an additional 131,251 shares during the last quarter. Alliancebernstein L.P. raised its stake in Glaukos by 56.5% during the first quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock worth $125,735,000 after buying an additional 461,386 shares during the last quarter. Primecap Management Co. CA raised its stake in Glaukos by 0.3% during the first quarter. Primecap Management Co. CA now owns 1,218,475 shares of the medical instruments supplier’s stock worth $119,922,000 after buying an additional 4,150 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in Glaukos by 34.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,084,184 shares of the medical instruments supplier’s stock worth $106,705,000 after buying an additional 277,033 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its stake in Glaukos by 18.7% during the first quarter. Driehaus Capital Management LLC now owns 973,625 shares of the medical instruments supplier’s stock worth $95,824,000 after buying an additional 153,502 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GKOS. The Goldman Sachs Group began coverage on shares of Glaukos in a research note on Wednesday, October 1st. They set a “buy” rating and a $103.00 target price for the company. UBS Group lifted their price target on shares of Glaukos from $125.00 to $134.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Citigroup decreased their price target on shares of Glaukos from $140.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. BTIG Research reaffirmed a “buy” rating and issued a $118.00 price target on shares of Glaukos in a research note on Wednesday, September 10th. Finally, Zacks Research downgraded shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $118.00.

Glaukos Stock Down 5.1%

Shares of NYSE GKOS opened at $82.55 on Friday. The stock has a market capitalization of $4.73 billion, a P/E ratio of -50.03 and a beta of 0.76. The company has a 50-day moving average price of $87.95 and a 200-day moving average price of $92.69. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to analysts’ expectations of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business’s revenue was up 29.7% on a year-over-year basis. During the same period last year, the company earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.